As previously reported, Guggenheim analyst Michael Schmidt initiated Rubius Therapeutics (RUBI) and Fate Therapeutics (FATE) with a Buy rating and Allogene Therapeutics (ALLO) with a Neutral rating as part of a broader research note of 3 biotechnology stocks that developed "innovative" next-gen cell therapy platforms. The analyst has a $25 price target on Fate Therapeutics, saying the company could "leapfrog" competitors by applying its induced pluripotent stem cell, or iPSC, platform toward "engineered off-the-shelf cancer immunotherapies in a dish". While still at an early stage, Schmidt says the platform may improve upon its initial shortcomings in first and also second generation cellular cancer immunotherapies toward a broad set of therapeutic areas. The analyst is also positive on the "unique red cell therapeutics platform" of Rubius Therapeutics and its upcoming proof-of-concept data in the second half of this year, with an "extremely broad" range of potential applications including rare genetic diseases to cancer and autoimmune diseases. Schmidt also assigns $25 price target to Rubius. For Allogene Therapeutics, Schmidt says he is positive on its potential front-runner status in bringing off-the-shelf CAR-T to market, but sees much of its potential having been priced into the stock.